Sinopharm Group Co Ltd (1099) fair value: what the stock is really worth
As of Oct 16, 2026: fair value (intrinsic value) of Sinopharm Group Co Ltd stock HK$47.16, price HK$15.72, upside +200.0%, quality 56 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 14, 2026.
How to read this chart
60‑month range HK$12.35 – HK$23.87 · fair‑value band HK$32.92 – HK$61.41 · the HK$15.72 price screens below the HK$47.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 14, 2026.
Follow Sinopharm Group Co in your weekly email
Every Wednesday you see whether Sinopharm Group Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China.
Show moreShow less
The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics.
This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers.
The Medical Devices Distribution segment distributes medical devices, as well as provides installation and maintenance services. The Retail Pharmacy segment operates and franchises a network of retail drug stores.
The Other Business segment engages in the distribution of laboratory supplies; manufacture and distribution of chemical reagents; and production and sale of pharmaceutical products.
The company rents and manages properties; distributes medical instruments and equipment, Chinese herbal medicines, antibiotics, and biological products; and offers information technology, investment, goods and technology import and export, business consulting, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services.
It also manages medical project investment, consulting, and technology training activities; and manufactures medicines. Sinopharm Group Co. Ltd. was founded in 2003 and is headquartered in Shanghai, the People's Republic of China.
Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Stock analysis
Sinopharm Group Co Ltd (1099) currently trades at HK$15.72, while our model-based Fair Value estimate is HK$47.16, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$85.65 per share, and 24 of the 24 models we run sit above the HK$15.72 price.
Bear case: the Asset-Based group reads lowest at HK$20.77, and 0 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$32.92 (bear) to HK$61.41 (bull), the price of HK$15.72 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sinopharm Group Co Ltd reported revenue of 575B CNY in FY2025 versus 521B CNY in FY2021, a compound +2.5%/yr. Reported net income was 7.2B CNY in FY2025, compounding −2.0%/yr from FY2021.
Key figures
Market cap HK$49.1B (≈ $6.3B) Mid · P/E ratio 5.6 · P/S ratio 0.11 · EPS (TTM) HK$3.30 · Dividend yield 5.0% · Net margin 1.2% · Return on equity 8.0% · Return on assets (EBIT) 5.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (medium confidence).
What moves the price
The share trades about 25% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 200%, 1099 screens cheaper than that median.
Fair Value models
BearHK$32.92Fair Value HK$47.16BullHK$61.41
Price HK$15.72 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (HK$2.01 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
Start year 2020 (pandemic). Over 10 years: +9.7% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+3.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.7%
Dividend (yield on the price)5.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−1.7% vs 5.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 3%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−22.6%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −23.8% a year for the price and +1.4% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 76 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)8.0% · Above median
Return on assets2.8% · Above median
Net margin (12 months)1.9% · Below median
Operating margin (12 months)3.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)−1.6% · Below median
Dividend yield (12 months)5.0% · Top 25%
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sinopharm Group Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1099
Frequently asked questions
Is Sinopharm Group Co Ltd (1099) overvalued or undervalued?
As of Oct 14, 2026, our model estimates a fair value of HK$47.16 versus a price of HK$15.72, about +200% upside (undervalued).
What is the fair value of 1099?
Our model-based fair value for Sinopharm Group Co Ltd is HK$47.16 (as of Oct 14, 2026), built from audited fundamentals. The current price: HK$15.72.
What is the quality score of 1099?
Sinopharm Group Co Ltd has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sinopharm Group Co Ltd (1099)?
Our model-based price target is the fair value of HK$47.16 (as of Oct 14, 2026) from 24 valuation models. Cautious scenario HK$32.92, optimistic scenario HK$61.41. It is a calculation from audited fundamentals, not an analyst target.
What is the Sinopharm Group Co Ltd stock forecast for 2026?
Our models put fair value at HK$47.16, about +200% upside versus a price of HK$15.72 (undervalued). Cautious scenario HK$32.92, optimistic scenario HK$61.41. The calculation is refreshed regularly with new filings.
What is the revenue of Sinopharm Group Co Ltd (1099)?
Sinopharm Group Co Ltd reported trailing-twelve-month revenue of about 572B CNY (latest available figure, as of Oct 14, 2026).
Does Sinopharm Group Co Ltd pay a dividend?
Sinopharm Group Co Ltd currently shows a dividend yield of 5.03% relative to its recent price (as of Oct 14, 2026).
What growth is priced into Sinopharm Group Co Ltd (1099)?
For today's price to be fair in a discounted-cash-flow model, Sinopharm Group Co Ltd would have to grow free cash flow by -22.6 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.7 % per year. As of Oct 14, 2026.
What discount rate (WACC) does the fair value of 1099 use?
Our models discount Sinopharm Group Co Ltd at 9.0 %: a base by market capitalisation (mid), damped by beta 0.44, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sinopharm Group Co Ltd that is -22.6 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Sinopharm Group Co Ltd (1099) delivered so far?
Over the past 5 years revenue at Sinopharm Group Co Ltd grew +4.7 % a year. The price currently implies -22.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sinopharm Group Co Ltd (1099) growing?
The median revenue growth in the sector is +5.7 % a year. That is the yardstick for the growth priced into Sinopharm Group Co Ltd (-22.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sinopharm Group Co Ltd (1099)?
The free-cash-flow yield on the price is 31.18 %: that much free cash flow Sinopharm Group Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sinopharm Group Co Ltd (1099)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sinopharm Group Co Ltd it is HK$47.16 per share (as of Oct 14, 2026), against a price of HK$15.72. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Sinopharm Group Co Ltd stock overvalued or undervalued in 2026?
As of Oct 14, 2026, 1099 trades below its calculated fair value: price HK$15.72, fair value HK$47.16, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1099?
No. The price is what the market pays today (HK$15.72); the fair value is what the company's own numbers justify (HK$47.16). For Sinopharm Group Co Ltd the two are HK$31.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sinopharm Group Co Ltd worth?
The market values Sinopharm Group Co Ltd at about HK$49.1B (market capitalisation, as of Oct 14, 2026). Per share that is HK$15.72; our models calculate a fair value of HK$47.16 per share.
What do the bullish and bearish scenarios say about 1099?
Our models span a range for Sinopharm Group Co Ltd: cautious scenario HK$32.92, base HK$47.16, optimistic HK$61.41 per share (as of Oct 14, 2026, price HK$15.72). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1099?
Sinopharm Group Co Ltd trades at a price-to-earnings ratio of 5.6 (as of Oct 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$47.16 is built from several models across several years. Other multiples: PEG 2.3, P/B 0.5, P/S 0.1.
What is the PEG ratio of 1099?
The PEG ratio of Sinopharm Group Co Ltd is 2.31 (P/E divided by earnings growth, as of Oct 14, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Sinopharm Group Co Ltd (1099)?
Balance-sheet figures for Sinopharm Group Co Ltd (as of Oct 14, 2026): return on equity 8.0%, debt of 0.04 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 1099 from its 52-week high?
Sinopharm Group Co Ltd trades at HK$15.72, about 25% below its 52-week high of HK$20.90 and 7% above the low of HK$14.70 (as of Oct 16, 2026). Distance from the high says nothing about value: that is what the fair value of HK$47.16 is for.
Which stocks are comparable to Sinopharm Group Co Ltd?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sinopharm Group Co Ltd stock attractive at the current price?
The data as of Oct 14, 2026: price HK$15.72, calculated fair value HK$47.16 (+200%), Quality Score 56/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1099 calculated?
We run Sinopharm Group Co Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$47.16, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Sinopharm Group Co Ltd currently trades 67 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sinopharm Group Co Ltd (1099)?
The closing price on Oct 16, 2026 was HK$15.72. Our model-based fair value is HK$47.16, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sinopharm Group Co Ltd right now?
The price is below even our cautious bear case (HK$32.92). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (56/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$32.92 to HK$61.41) leaves room in how you read the outcome.
Where does the earnings growth of Sinopharm Group Co Ltd (1099) come from?
Earnings per share at Sinopharm Group Co Ltd grew +6.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +9.3 %, EBIT margin −3.1 %, tax rate −0.5 %, residual (interest, one-offs) +1.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Sinopharm Group Co Ltd
How large is the market capitalisation of Sinopharm Group Co Ltd (1099)?
The market capitalisation of Sinopharm Group Co Ltd is HK$49.1B (≈ $6.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sinopharm Group Co Ltd (1099)?
The price-to-sales ratio of Sinopharm Group Co Ltd is 0.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sinopharm Group Co Ltd (1099)?
Earnings per share at Sinopharm Group Co Ltd are HK$3.30 (price ÷ EPS = P/E 5.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sinopharm Group Co Ltd (1099)?
The dividend yield of Sinopharm Group Co Ltd is 5.0% (payout 23.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sinopharm Group Co Ltd (1099)?
The net margin of Sinopharm Group Co Ltd is 1.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sinopharm Group Co Ltd (1099)?
The return on equity (ROE) of Sinopharm Group Co Ltd is 8.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sinopharm Group Co Ltd (1099)?
On an EBIT basis the return on assets of Sinopharm Group Co Ltd is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sinopharm Group Co Ltd (1099)?
The operating margin of Sinopharm Group Co Ltd is 3.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sinopharm Group Co Ltd (1099)?
Revenue at Sinopharm Group Co Ltd is growing −1.6% versus a year earlier (3y avg +1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sinopharm Group Co Ltd (1099)?
Earnings per share at Sinopharm Group Co Ltd are growing +0.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Sinopharm Group Co Ltd (1099) carry?
The net debt of Sinopharm Group Co Ltd is 47.0B CNY (fiscal year 2025, ≈ 3.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sinopharm Group Co Ltd in the live analysis
One click puts Sinopharm Group Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 14, 2026